View Older Stories View More Recent Stories
-
Leerink Partners Reiterates Outperform Rating on Viking Therapeutic (VKTX)
-
H.C. Wainwright on Viking Therapeutic (VKTX): 'We expect the Phase 3 program to continue building on this foundation'
-
Morgan Stanley on Viking (VKTX): 'we view initiation of large Ph3 studies on schedule as an incremental positive'
-
Cantor Fitzgerald Starts Viking Therapeutic (VKTX) at Overweight
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Misses Q1 EPS by 8c
-
Viking Therapeutic (VKTX) PT Lowered to $100 at Oppenheimer
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Goldman Sachs Starts Viking Therapeutic (VKTX) at Neutral
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
-
Will Pfizer step into the obesity ring? Wolfe Research answers
-
Viking Therapeutics (VKTX) Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Strength Said to be Tied to Unconfirmed M&A Chatter
-
Citi Starts Viking Therapeutic (VKTX) at Neutral
-
Viking Therapeutic (VKTX) PT Lowered to $95 at Truist Securities
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Misses Q4 EPS by 4c
-
Viking Therapeutics (VKTX) call put ratio 16 calls to 1 put with a focus on February 7 weekly calls into quarter results
-
Viking Therapeutics (VKTX) ticks higher on industry chatter
-
Viking Therapeutics (VKTX) call put ratio 6.3 calls to 1 put with a focus on January 24 weekly calls
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) call put ratio 1.3 calls to 1 put as share price trends lower
-
Truist Securities Reiterates Buy Rating on Viking Therapeutic (VKTX) 'As Competitor Data Disappoint'
-
Viking Therapeutics (VKTX) Initiates Phase 2 VENTURE-Oral Dosing Trial of VK2735
-
Viking Therapeutics (VKTX), Others Gain After Novo Nordisk (NVO) Data Falls Short of Expectations
-
Viking Therapeutics (VKTX) call put ratio 2. Calls to 1 put with focus on February calls
-
Viking Therapeutics (VKTX) weakness tied to Merck's (MRK) Deal for GLP-1 Receptor Agonist
-
Piper Sandler Starts Viking Therapeutic (VKTX) at Overweight
-
BTIG Reiterates Viking Therapeutic (VKTX) at Buy, 'continue to see sub-q VK2735 remaining highly competitive'
-
B.Riley Starts Viking Therapeutic (VKTX) at Buy
-
After-hours movers: Dolby Laboratories, Powell Industries, Keysight Technologies
-
Viking Therapeutics (VKTX) Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting
-
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Reports New Data from VK2735 Obesity Program
-
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
BTIG Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Tops Q3 EPS by 2c
-
Viking Therapeutics (VKTX) October 25 weekly option implied volatility bid into quarter results
-
Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
-
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) Reports Results from Phase 1b Clinical Trial of VK0214
-
Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
-
Morgan Stanley Reiterates Overweight Rating on Viking Therapeutic (VKTX)
-
Oppenheimer Reiterates Outperform Rating on Viking Therapeutic (VKTX)
-
Viking Therapeutics (VKTX) call put ratio 1.8 calls to 1 put with focus on October 70 calls.
-
Viking Therapeutics (VKTX) call put ratio 12.1 calls to 1 put with focus on September 70 and 71 calls
-
Novo Nordisk shares fall after Monlunabant phase 2a trial results; Viking jumps
-
Viking Therapeutics (VKTX) ticks higher after Novo Nordisk's monlunabant obesity data

